Navigation Links
Peregrine Pharmaceuticals Receives Approval to Begin New Phase II Trial of Bavituximab in Patients With Metastatic Breast Cancer
Date:11/16/2007

ticipating in assessing bavituximab have extensive experience in conducting mid and late stage cancer studies that adhere to FDA and international standards, and we look forward to working with them to ensure the timely conduct of this important Phase II trial."

Tumor response in this new study will be evaluated using Response Evaluation Criteria in Solid Tumors (RECIST) parameters. The trial is being conducted according to International Conference on Harmonization (ICH) and Good Clinical Practices (GCP) standards.

According to the World Health Organization, metastatic breast cancer is the most commonly diagnosed cancer in women, and is second only to lung cancer as a leading cause of female cancer deaths. The National Cancer Institute estimates that 178,480 U.S. women will be diagnosed with cancer of the breast in 2007 and 40,460 women will die of the disease.

Bavituximab is a monoclonal antibody that binds to a phospholipid called phosphatidylserine that is usually located inside normal cells, but which becomes exposed on the outside of the cells that line the blood vessels of tumors, creating a specific target for anti-cancer treatments. Bavituximab is believed to help mobilize the body's immune system to destroy the blood vessels needed for tumor growth and spread. In a Phase lb trial in advanced cancer patients, bavituximab plus chemotherapy appeared to have a safety profile consistent with chemotherapy alone and showed positive signs of clinical activity, achieving objective response or disease stabilization in 50% of the evaluable patients. A protocol for a Phase II trial of bavituximab in combination with the chemotherapy drugs paclitaxel and carboplatin in patients with metastatic breast cancer is currently undergoing regulatory review in India. A protocol for a Phase II trial of bavituximab in combination with the chemotherapy drugs paclitaxel and carboplatin in patients with non-small cell lung cancer (NSCLC) is also under regulatory rev
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Positive Results From Peregrine Pharmaceuticals Bavituximab Phase l HCV Trial Presented at AASLD Meeting
2. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
3. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
4. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
5. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
6. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
7. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
8. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
9. Amylin Pharmaceuticals to Webcast Corporate Overview During 43rd Annual Meeting of the European Association for the Study of Diabetes
10. Major Pharma Clinical Case Studies From Amgen, AstraZeneca, GSK, Intermune, Cephalon Inc, Sunesis Pharmaceuticals and Dartmouth Medical School During Fall Clinical Focused Programs
11. Provectus Pharmaceuticals, Inc. releases summary results of phase 1 metastatic melanoma study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... research co-funded by the Engineering and Physical Sciences ... of the UK,s vital industrial control systems which ... electricity grid, and the rail network. , ... from hackers or malware infiltrating the systems behind ... Institute in Trustworthy Industrial Control Systems (RITICS), based ...
(Date:10/1/2014)... 01, 2014 Marriagelifeinsurance.com has released ... insurance for retired couples. , Senior citizens can ... security for their loved ones. A joint policy is ... persons pass away. , Life insurance can be ... insurance can even be purchased online, as the application ...
(Date:10/1/2014)... Phoseon Technology, the pioneer in developing ... business worldwide. This rapid growth includes increased hiring for ... efforts. The company has experienced average annual growth rates ... this growth to continue in the future as new ... , “We are very pleased that UV ...
(Date:10/1/2014)... 01, 2014 Beverly Hills licensed Clinical ... is celebrating 20 years of private practice in her ... people to achieve greater joy and fulfillment in their ... warning signs and suggestions for anyone who suspects they ... “Believe it or not, it’s not always easy ...
(Date:10/1/2014)... Anti Aging Clinic (AntiAgingClinic.ca), the Greater ... of choice, is announcing a discounted cost on Botox ... , “We’re doing this because we want to give ... skin clinic in Toronto,” says Dr. Brian Sieber, founder ... Anti Aging Clinic, including laser facials, genesis laser facials, ...
Breaking Medicine News(10 mins):Health News:£2.5 million to recognize and reduce cyber-attack threats to critical infrastructure 2Health News:Elderly Life Insurance - Find Life Insurance for Retired Couples! 2Health News:Phoseon Technology Continues to Drive Growth Worldwide 2Health News:Prominent Beverly Hills Psychologist Dr. Kathleen Mojas Celebrating 20 Years in Private Practice Identifies Common Warning Signs That You May Be In a Toxic Relationship. 2Health News:Prominent Beverly Hills Psychologist Dr. Kathleen Mojas Celebrating 20 Years in Private Practice Identifies Common Warning Signs That You May Be In a Toxic Relationship. 3Health News:Anti Aging Clinic, the GTA’s Premier Provider of Anti Aging Treatments, Announces Deal on Units of Botox 2
... June 13 (Pink Sheets: ICTY) As of,June 11, ... that is,going to completely revamp the company and move ... very tight and secure team of corporate,individuals are in ... must be addressed prior to the release of any ...
... HILL, N.C., June 13 Market competition ... interest of the most highly,qualified clinical investigators. ... clinical investigators to their studies win an ... Best Practices, LLC,s white paper "Recruiting and ...
... could detect disease sooner, when it,s more treatable , , FRIDAY, ... development of pancreatic cancer have been identified by U.S. researchers, ... to develop a blood test to detect this type of ... , "Our team identified, for the first time, protein ...
... Paris, France, Friday 13 June 2008: Rheumatoid ... (PsA) patients should undergo compulsory cardiovascular (CV) risk ... adapted to the increased CV risk in inflammatory ... ,Cardiovascular Risk Management in RA, recommended today at ...
... End of Life Urges Congress to Preserve ... Compassionate End-of-Life Care, WASHINGTON, June ... Payment Advisory Commission (MedPAC),reported that the rapid growth of the Medicare ... and more spending per,beneficiary. According to the report, "Evaluating Medicare,s Hospice,Benefit," ...
... 13 June 2008: A new DNA microarray chip can ... arthritis (RA), as presented today at EULAR 2008, the ... Paris, France. The chip (called the ,ARTchip,) has yielded ... in anticipating likely disease progression and prognosis and thereby ...
Cached Medicine News:Health News:EyeCity.com, Inc. Changes Ownership and Moves Into a New Direction 2Health News:Pancreatic Cancer Biomarkers Found 2Health News:CV risk management should be mandatory in RA and other types of inflammatory rheumatic disease 2Health News:CV risk management should be mandatory in RA and other types of inflammatory rheumatic disease 3Health News:More Data Needed Before Changing Medicare Hospice Funding, Report Finds 2Health News:More Data Needed Before Changing Medicare Hospice Funding, Report Finds 3Health News:Novel DNA microarray chip predicts functional impairment and remission in rheumatoid arthritis 2
(Date:9/30/2014)... Sept. 30, 2014 /CNW/ - Protecting the health and safety of ... Canada uses the appropriate powers and tools at its disposal to ... and quality standards. To that end, Health ... the import into Canada of all drug ... They are: , Apotex Pharmachem India Pvt Ltd ...
(Date:9/30/2014)... , Sept. 30, 2014  Hologic, Inc. (NASDAQ: ... , Hologic,s President and Chief Executive Officer, will preside ... October 1, the first day of Breast Cancer Awareness ... Company,s campaign focused on the important benefits of Hologic,s ... the FDA as clinically superior to traditional mammography. ...
(Date:9/30/2014)... -- This study provides an analysis of the ... nuclear imaging informatics, PET imaging informatics, and multimodality ... size of the market based on its historic ... growth based on the current drivers and restraints, ... the broader markets for imaging equipment, advanced visualization, ...
Breaking Medicine Technology:Statement by the Honourable Rona Ambrose on the import ban of drug products from three plants in India 2Hologic to Kick Off National Breast Cancer Awareness Month at the October 1 NASDAQ Stock Market Opening Bell Ceremony 2Hologic to Kick Off National Breast Cancer Awareness Month at the October 1 NASDAQ Stock Market Opening Bell Ceremony 3Analysis of the US Molecular Imaging Informatics Market 2Analysis of the US Molecular Imaging Informatics Market 3
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: